Instem plc announces that it has appointed Riaz Bandali as an independent non-executive director to the Board effective 1 December 2021. Riaz will also be appointed to the Audit and Remuneration Committees. Riaz has spent his entire career in the healthcare and life sciences industries in a variety of strategic, commercial and operational roles at senior level, also including exposure to fundraising and M&A activity. Riaz is currently CEO of Emerald Health Therapeutics, listed on the Canadian Stock Exchange (CSE: EMH), a role he has held since 2019. Prior to that, Riaz was with Syneos Health for nine years, firstly leading their Early Stage Contract Research Services business then becoming Chief Innovation Officer and more recently as President, Early Phase Development and Translational Sciences, with responsibility for a team of 900 people globally. He started his career in 1994 spending eight years at MDS Capital Corp. as a Venture Capital investor, as part of a a $1bn Canadian Health & Life Sciences fund. In 2002, Riaz moved into industry with MDS portfolio company MDS Sciex until 2006, when he moved to MDS Pharma Services (now Celerion), a global clinical pharmacology and bioanalysis business. Between 2008 and 2010, he was Senior Vice President at AB Sciex and Molecular Devices (part of Danaher), leading M&A and key growth strategies.